Galactosylceramide beta-galactosidase in Krabbe disease: partial purification and characterization of the mutant enzyme

Galactosylceramide β-galactosidase (EC 3.2.1.46) has been partially purified from liver of a patient who died of Krabbe disease. Approximately 700-fold purification was achieved by solubilization, adsorption with immobilized concanavalin A, gel filtration through Bio-Gel A-1.5m and chromatography on immobilized sphingosine. The relative increase in crossreacting material and residual galactosylceramidase and lactosylceramidase I activities of the mutant enzyme was essentially identical to that obtained for the enzyme partially purified by the same procedure from normal liver control. An apparent molecular weight of about 750,000 and similar electrophoretic mobilities were observed for both enzymes. In contrast, catalytic properties and stability of the enzyme protein were severely affected in the mutant as compared to the normal enzyme. The apparent K_m values of the mutant enzyme for β-galactosidase activities toward galactosylceramide and lactosylceramide in the presence of pure sodium taurocholate were 14 and 4 times, respectively, higher than the normal values. Incubation for 4 min at 52 °C or dialysis against 1.3 m urea caused a 50% loss of residual enzymatic activity of the mutant enzyme, whereas a 35-min incubation or dialysis against 5.6 m urea was required for 50% inactivation of the normal enzyme. These findings indicate that the mutation in Krabbe disease leads to synthesis of normal quantities of catalytically and structurally altered protein.